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SUMMARY
RNAi is widely appreciated as a powerful regulator of
mRNA translation in the cytoplasm of mammalian
cells. However, the presence and activity of RNAi
factors in the mammalian nucleus has been the sub-
ject of considerable debate. Here, we show that
Argonaute-2 (Ago2) and RNAi factors Dicer, TRBP,
and TRNC6A/GW182 are in the human nucleus and
associate together in multiprotein complexes. Small
RNAs can silence nuclear RNA and guide site-
specific cleavage of the targeted RNA, demon-
strating that RNAi can function in the human nucleus.
Nuclear Dicer is active and miRNAs are bound to nu-
clear Ago2, consistent with the existence of nuclear
miRNA pathways. Notably, we do not detect loading
of duplex small RNAs in nuclear extracts and known
loading factors are absent. These results extend
RNAi into the mammalian nucleus and suggest that
regulation of RNAi via small RNA loading of Ago2 dif-
fers between the cytoplasm and the nucleus.
INTRODUCTION
Since the discovery of mammalian RNAi (Elbashir et al., 2001),
over 50,000 reports have described the use of small interfering
RNAs (siRNAs). Almost all of these studies have assumed that
the regulation of RNAi and its silencing activity occurs in the
cytoplasm (Gurtan and Sharp, 2013). Whether RNAi can function
in the mammalian nucleus and regulate processes like transcrip-
tion or splicing has remained unclear (Castel and Martienssen,
2013; Harel-Bellan et al., 2013). Likewise, what role the nuclear
compartment might play in the regulation of RNAi pathways is
unknown. These uncertainties have significantly hampered
investigation of nuclear RNA biology and the development of nu-
clear RNAi as a laboratory tool and potential therapeutic.
The assumption that mammalian RNAi is confined to the
cytoplasm has been supported by reports that siRNAs cannot
silence introns (Vickers et al., 2003; Zeng and Cullen, 2002). In
addition, microscopy has shown a cytoplasmic distribution of
RNAi factors, such as Argonaute-2 (Ago2), to P-bodies and the
endoplasmic reticulum (ER) (Ikeda et al., 2006; Stalder et al.,
2013). Some laboratories, however, have suggested that Ago2
and other RNAi factors can be found in the nucleus (Ando
et al., 2011; Chu et al., 2010; Doyle et al., 2013; Ohrt et al.,
2012; Ru¨del et al., 2008; Till et al., 2007; Weinmann et al.,
2009). siRNAs have been reported to silence the nuclear
enriched RNAs 7SK and U6 (Ohrt et al., 2008; Robb et al.,
2005). Although nuclear RNAi activity and localization of RNAi
factors to the nucleus have been reported previously, questions
about the purity of cell extracts (Holding, 2004), the resolution of
localization studies, and nucleocytoplasmic transport of the RNA
targets and products of RNAi have kept nuclear RNAi a contro-
versial subject.
MicroRNAs (miRNAs) enter the RNAi pathway by binding Ago
proteins (Gurtan and Sharp, 2013). In the cytoplasm, miRNAs
guide Ago proteins to 30 untranslated regions and destabilize
or inhibit translation of mRNAs (Bartel, 2009; Gurtan and Sharp,
2013; Valencia-Sanchez et al., 2006). miRNAs have also been
found in the nucleus (Jeffries et al., 2011; Katahira and Yoneda,
2011; Liao et al., 2010), but their biological roles are unknown.
Both synthetic siRNAs and microRNAs have been shown to
induce changes in splicing (Allo´ et al., 2009; Liu et al., 2012)
and transcription (Janowski et al., 2007; Li et al., 2006; Matsui
et al., 2013;Morris et al., 2004). However, themechanismsmedi-
ating these processes remain controversial, due in part to the
debate over the presence and activity of nuclear RNAi factors.
During cytoplasmic RNAi, small RNA loads into the RNA
induced silencing complex (RISC), the complex recognizes a
complementary RNA target, and target cleavage can occur at
a specific site (Wilson and Doudna, 2013). Several factors have
been implicated in the loading of small RNAs into Ago proteins
(programming) and thematuration of RISC in human cells. These
include the protein folding chaperones Hsp90 and Hsc70
(Iwasaki et al., 2010) and the component 3 promoter of RNAi
(C3PO) complex composed of Translin and TRAX (Ye et al.,
2011). Hsp90/Hsc70 are implicated in chaperone-like mecha-
nisms that may open Ago proteins to accommodate the initial
binding of a duplex RNA (Iwasaki et al., 2010). In addition,
Hsp90 chaperone activity in RNAi programming and RISCmatu-
ration has been shown to be dependent on the presence of
cochaperones, including Aha1, FKBP4/5, Cdc37, and p23
(Martinez et al., 2013; Pare et al., 2013). C3PO possesses
single-strand nuclease activity and has been shown to accel-
erate passenger strand RNA removal from Ago to mature the
RISC complex (Liu et al., 2009; Ye et al., 2011).
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Ago2 binds small duplex RNA and forms the core of RISC
(Hammond et al., 2000; MacRae et al., 2008; Wilson and
Doudna, 2013). Other key players involved in RISC include the
pre-miRNA processing enzyme Dicer, the TAR RNA-binding
protein (TRBP), and TNRC6A (GW182 homolog) (Daniels and
Gatignol, 2012; Lazzaretti et al., 2009; Ma et al., 2012; MacRae
et al., 2008). Ago-RISC complexes recognize RNAs complemen-
tary to the guide strand (Hammond et al., 2000). When the guide
strand is fully complementary to target RNA, Ago2 can catalyze
site-specific phosphodiester bond cleavage (‘‘slicer’’ activity)
(Liu et al., 2004; Meister et al., 2004; Wang et al., 2008).
To resolve the controversy over mammalian nuclear RNAi, we
investigated the localization, interaction, and activity of known
RNAi factors in human cell nuclei. Here, we show that Ago2
and other RNAi factors are present in the nucleus and can asso-
ciate in multiprotein complexes. Small RNAs in complex with
Ago2 can silence nuclear RNA and induce site-specific cleav-
age. Nuclear Dicer is catalytically active and miRNAs are bound
to nuclear Ago2. In contrast, we did not detect loading of duplex
RNA in nuclei and most RISC loading factors are absent. These
results place the protein machinery necessary for RNAi recogni-
tion inside the mammalian cell nucleus but suggest key differ-
ences between nuclear and cytoplasmic RNAi.
RESULTS
RNAi Factors Are Present in Human Cell Nuclei
We began our study by using HeLa cells to examine the localiza-
tion of Ago2, the catalytic core of RNAi (Liu et al., 2004). We used
wide-field immunoepifluorescence microscopy with blind
deconvolution because the technique is ideal for rapid and
high-sensitivity 3D imaging for thin specimens such as cells in
monolayer culture (Shaw, 2006). In some cases, we also used
confocal immunofluorescence microscopy for comparison.
The success of immunofluorescence often depends on condi-
tions like fixation and permeabilization, antibody binding, and
cell type (Katikireddy and O’Sullivan, 2011). To improve detec-
tion of nuclear proteins, we used protocols designed to facilitate
entry of antibody into the nucleus (Spector, 2011).
Our microscopy revealed a substantial amount of Ago2 in
the nucleus in addition to the expected distribution within the
cytoplasm. Images of slices through several micrometer thick
sections along the z axis, combined with 3D rendering of
composite focal sections, revealed Ago2 within the nuclear
compartment (Figure 1; Movie S1). The application of two addi-
tional antibodies against human Ago2 produced similar results
(Figures S1A–S1C), confirming that nuclear visualization was
not due to off-target immunoreactivity. We also observed Ago2
in the nuclei of T47D breast cancer cells and fibroblast cells
(Figures S1D–S1F), indicating that nuclear Ago2 is not cell type
specific. Confocal microscopy confirmed nuclear localization
of Ago2 (Figures S1G and S1H). We also used wide-field immu-
nofluorescence microscopy to test localization of Dicer, TRBP,
and TNRC6A and observed staining in the nucleus as well as in
the cytoplasm (Figures S1I–S1K). These results using different
microscopy platforms, cell lines, and detection reagents suggest
the nuclear presence of the protein machinery that enables
RNAi.
As a second method for testing nuclear localization, we
used cellular fractionation and western blot analysis to evaluate
the levels of Ago2 and other RNAi factors in the nucleus. We
developed a stepwise protocol for isolating cytoplasmic,
whole nuclear, nucleoplasmic (soluble nuclear), and chromatin-
associated fractions from the same cell population. Fractions
were used for various assays, including protein and RNA detec-
tion, chromatographic or biochemical fractionation, and enzy-
matic assays (Figure 2A).
RNAi factors can localize to the ER (Stalder et al., 2013). This
poses a challenge for accurate assessment of localization inside
of nuclei because the ERmembrane is contiguous with the outer
nuclear membrane (Hetzer, 2010). To ensure efficient removal of
ER protein contamination, we tested detergents and conditions
for preparation of nuclear extracts (Michelsen and von Hagen,
2009). Nuclei were washed with buffers containing different
detergents and then visualized by fluorescence microscopy
using DAPI and ER tracker, a fluorescent dye that binds the
sulphonylurea receptor class of ER integral membrane proteins.
Our microscopy indicated that the addition of 0.3% NP-40
was most efficient at removing ER contamination (Figure 2B).
Western blots confirmed the absence of both ER lumen and
ER membrane proteins from nuclear extracts (Figure 2C).
Western blot analysis of purified nuclei revealed endogenous
Ago2, Dicer, TRBP, and TRNC6A in the nuclei of multiple human
cell lines (Figure 2D). Protein markers for the cytoplasm, ER, and
mitochondria were absent from nuclear preparations, consistent
with stringent isolation of nuclei. Quantitation of western blots
revealed relative nuclear abundances ranging from 40% to
Figure 1. Microscopy Reveals Ago2 in Human Cell Nuclei
Immunofluorescence microscopy of endogenous Ago2 in HeLa cells. z
sections are stacked (6 mm), projected three-dimensionally, and rotated to
highlight nuclear staining. Scale bar represents 3 mm.
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50% (Figure 2E). We also observed the other human Ago vari-
ants, Ago1, Ago3, and Ago4, in our nuclear preparations (Fig-
ure S2). Combined with microscopy, our analysis of cell fractions
demonstrates that the basic machinery necessary to execute
RNAi is present in human cell nuclei.
Nuclear RNAi Factors Can Stably Associate in
Multiprotein Complexes
RNAi factors interact to form RISC and execute RNAi in the
cytoplasm (MacRae et al., 2008; Wilson and Doudna, 2013). To
determine whether nuclear RNAi factors also interact, we tested
coimmunoprecipitations of nuclear Ago2, Dicer, TNRC6A, and
TRBP. These coimmunoprecipitations revealed a network of in-
teractions between RNAi factors (Figure 3A).
To further support the observed association of RNAi factors
with Ago2 in nuclei, we generated T47D cells stably expressing
FLAG-HA-tagged Ago2 (FHA-Ago2). Immunoprecipitation of
FHA-Ago2 with FLAG antibody confirmed copurification of
Dicer, TNRC6A, and TRBP (Figure 3B). Coimmunoprecipitation
of Ago2 and Dicer or Ago2 and TNRC6A were also observed in
nuclear extracts treated with RNase A, indicating that the asso-
ciation of RNAi factors was independent of RNA (Figure 3C).
To visualize the association of TNRC6A and Ago2 inside of
cell nuclei, we performed immunofluorescence microscopy.
These experiments revealed colocalization of Ago2 and TNRC6A
staining within HeLa nuclei (Figures 3D and S3). Colocalization of
Ago2 and TNRC6A is consistent with the suggestion from our
coimmunoprecipitation results that nuclear RNAi factors can
form complexes.
To further characterize nuclear complexes containing RNAi
factors, we separated nuclear extracts by size and charge.
Fractionation by size-exclusion chromatography revealed high
molecular weight complexes containing all four RNAi factors
(Figure 3E). To test the involvement of RNA in complex formation,
we treated extracts with RNase A and observed that RNA was
not required. When high molecular weight fractions containing
RNAi factors were further separated by anion-exchange chro-
matography, RNAi factors continued to coelute (Figure 3F)
indicating that the complexes were sufficiently stable to survive
tandem purification schemes. Taken together, these results
demonstrate that nuclear RNAi factors can form stable multipro-
tein RISC-like complexes.
To compare nuclear and cytoplasmic RNAi protein com-
plexes, we performed similar size-exclusion chromatography
with cytoplasmic extract (Figure 3G). The retention time of
Ago2, Dicer, and TNRC6A was similar in cytoplasmic fractions
compared to the nuclear fraction. TRBP, however, eluted later
regardless of the presence or absence of RNase A. As an alter-
nate test for the stability of complexes containing RNAi factors,
we fractionated nuclear and cytoplasmic extracts by adding
increasing amounts of ammonium sulfate. Although all four
RNAi factors precipitated from nuclear extract at 20% ammo-
nium sulfate, a 40% concentration was required for precipitation
from cytoplasmic extract (Figure 3H). These results from
Figure 2. RNAi Factors Are Present in Nuclear Extracts
(A) Schematic of cellular fractionation protocol.
(B) Fluorescent imaging of intact HeLa nuclei after isolation with buffers con-
taining different detergents. ER membrane is stained yellow with ER Tracker
dye, DAPI staining of nuclei.
(C) Western blot analysis of cytoplasmic and nuclear fractions prepared with
buffers containing different detergents. Calreticulin is a marker for the ER
lumen. Calnexin is a marker for the ER membrane.
(D)Western blot of RNAi factors and subcellular markers from cytoplasmic and
nuclear fractions prepared with 0.3% NP-40. Oxphos is a marker for mitch-
odondria, Lamin A/C is a marker for nuclear matrix, and tubulin is a marker for
cytoplam.
(E) Quantification of RNAi factors fromwestern blots of HeLa, T47D, fibroblast,
and A549 cells shown in (D). Error bar is ±SEM.
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fractionation by either chromatography or precipitation reveal
the formation of RISC-like complexes, but also suggest that
the exact composition of complexes in the nucleus and the
stability of their association differs from that observed in the
cytoplasm.
RNAi Is Active in the Nucleus
After demonstrating that RNAi factors were present in human
cell nuclei, we investigated whether they could also direct
silencing of nuclear RNA substrates. We examined the
silencing within cytoplasmic, nucleoplasmic, and chromatin-
associated cell fractions. Our target RNAs were Malat1 and
Neat1, long noncoding RNAs (lncRNAs) primarily associated
with chromatin (Figure 4A) (Dodd et al., 2013). For comparison,
we also targeted ribosomal protein L30 (RPL30) and peptidyl-
prolyl isomerase A (PPIA) mRNAs, which are primarily
cytoplasmic.
We treated cells with siRNAs targeting each RNA transcript,
fractionated the cells, and then used quantitative PCR (qPCR)
tomeasure RNA levels. As typically observed with siRNAs, levels
of all four RNA transcripts were reduced in the cytoplasmic
fraction (Figure 4B).We observed a similar reduction of transcript
levels in nucleoplasmic and chromatin fractions, consistent with
RNAi activity in nuclei (Figure 4B).
Cleavage at a predicted location is a diagnostic for substrate
processing by Ago2. Therefore, we used 50 rapid amplification
of cDNA ends (50 RACE) to further test whether silencing of
RNA in the nucleoplasm and on chromatin was due to Ago2-
mediated cleavage.We isolated RACEproducts and sequencing
revealed that site-specific cleavage had occurred at the pre-
dicted phosphodiester bond in all cellular fractions for Malat1
(Figures 4C, S4A, and S4B). Identification of the predicted
RACE products associated with chromatin and in nucleoplasm
is additional evidence for nuclear RNAi activity.
Figure 3. RNAi Factors Associate in Multiprotein Complexes in the Nucleus
(A) Coimmunoprecipitation (coIP) of endogenous RNAi factor from HeLa nuclear extract. The antibodies used for the western blot detection are noted to the right,
whereas the antibodies used for immunoprecipitations are on top.
(B) CoIP of RNAi factors from T47D cells expressing FLAG-HA-tagged Ago2 (FHA-A2). HeLa nuclear extract serves as a negative control. Input is extract prior to
immunoprecipitation.
(C) CoIP of Ago2 with Dicer or TNRC6A from T47D nuclear extracts treated with RNase A.
(D) Immunofluorescence of Ago2 and TNRC6A in HeLa cells indicates overlap and colocalization of immunostaining. z stacks (3 mm thickness taken in 0.1 mm
slices) are projected in 3D. The colocalization channel was generated in Imaris (Bitplane). Scale bar represents 5 mm.
(E)Western analysis of fractions from separation of HeLa cell nuclear extract by size exclusion. Extracts were prepared either with our without treatment by RNase
A. Western blot antibodies are shown to the right. Sample fractions are below. Histone H3 is marker for high molecular weight chromatin.
(F) Western analysis of fractions after anion-exchange chromatography of nuclear extract Fraction C from Figure 5E. FT, column flowthrough.
(G) Western analysis of fractions HeLa cytoplasmic extract after size-exclusion chromatography. Extracts were prepared either with our without treatment with
RNase A.
(H) Effect of ammonium sulfate precipitation of RNAi factors from T47D nuclear or cytoplasmic extracts. Western blot antibodies are shown to the right and
ammonium sulfate concentrations (% saturation) are shown above.
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To further investigate the potential for nuclear Ago2 to cleave
RNA substrates, we set up an in vitro cleavage assay using Ago2
from either cytoplasmic or nuclear fractions and a radiolabeled
RNA substrate derived from luciferase (Luc) mRNA (Elbashir
et al., 2001). Cells were transfected with a duplex RNA (siLuc)
complementary to the Luc RNA substrate or a duplex RNA con-
taining two central mismatches (siLuc_mm). Central mismatches
are known to disrupt slicer activity (Wang et al., 2008). Ago2 was
then immunoprecipitated from either the cytoplasmic or nuclear
fractions and incubated with the radiolabeled target RNA sub-
strate. Reactions were then resolved on denaturing polyacryl-
amide gels to visualize cleavage products.
Ago2 immunoprecipitated from both cytoplasmic and nuclear
extracts of cells treated with siLuc caused sequence-specific
Figure 4. RNAi Is Active in the Human Cell
Nucleus
(A) Quantification RNA distribution in HeLa sub-
cellular fractions by qPCR. Error bar is ±SEM.
(B) Quantification by qPCR of siRNA-mediated
lncRNA and mRNA knockdown in HeLa subcellu-
lar fractions. Error bar is ±SEM
(C) 50 RACE to detect siRNA-mediated Ago2
cleavage of Malat1 in chromatin-associated
RNA fractions. Arrow indicates specific cleavage
product.
(D) Cleavage of a 50-radiolabeled luciferase RNA
substrate by Ago2 isolated from cytoplasmic or
nuclear fractions. T1, RNase T1 cleavage; OH,
alkaline hydrolysis; (+) CTRL, synthetic cleavage
product. The region overlapped by the siRNA is
noted.
(E) FISH showing that Malat1 speckles in HeLa
cells are lost upon treatment with siMalat1 siRNA.
z stacks are 5 mm thickness. siLuc, mock treat-
ment. Scale bar represents 5 mm.
cleavage of the Luc substrate (Figure 4D,
lanes 6 and 9). In contrast, Ago2 from
cytoplasmic and nuclear extracts of cells
treated with siLuc_mm did not support
cleavage (Figure 4D, lanes 7 and 10).
A lack of cleavage for siLuc_mm is ex-
pected based on the known slicer mech-
anism of Ago2, which requires perfect
complementarity at the targeted bond
(Wang et al., 2008). These results demon-
strate sequence-specific slicer activity for
nuclear Ago2.
To visualize RNAi-mediated activity
inside cell nuclei, we targeted Malat1
RNA with a siRNA (siMalat1) and per-
formed fluorescence in situ hybridization
(FISH). FISH prior to siMalat1 treatment
revealed distinct nuclear speckles. Upon
treatment with siMalat1, the Malat1
speckles disappeared. In contrast to the
disappearance of speckles after treat-
ment with siMalat1, a siRNA with no
cellular target (siLuc) had no effect
(Figures 4E, S4C, and S4D). Taken together, several lines of
evidence are consistent with RNAi slicer activity in cell nuclei,
including (1) siRNA-mediated reduction in the levels of nuclear
RNA targets, (2) site-specific cleavage of nuclear RNA targets
at a position diagnostic for RNAi, (3) cleavage of target RNA by
Ago 2 isolated from nuclear extract, and (4) visualization of
reduced target RNA within cell nuclei.
miRNAs in Cell Nuclei
We evaluated the localization of miRNAs within cell nuclei and
their association with Ago2. Sequencing of small RNAs revealed
that out of 456 miRNA species identified in the whole cell, 346 of
them also exist in cell nuclei, suggesting that roughly 75% of
miRNAs in the cytoplasm are shuttled into the cell nucleus
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(Figure 5A). The identities of many of the top 18 ranked miRNAs,
based on the number of obtained sequencing reads, were the
same between nuclei and whole cell (Figures 5B and 5C), indi-
cating a similar distribution of abundant miRNA species in the
cytoplasm and the nucleus.
We then examined the association of miRNAs with Ago2 in cell
nuclei. Ago2 was immunoprecipitated from nuclear extract using
a nonspecific mouse immunoglobulin G (IgG) as a negative
control. Bound small RNAs were isolated and sequenced on a
Helicos single molecule sequencer using direct RNA sequencing
mode. In this mode, the steps of making complementary DNA
and PCR amplification are avoided so that potential sequencing
biases are eliminated. The number of sequencing reads better
represents the original miRNA expression level. We prepared
two biological replicates and averaged the sequencing read
number for each small RNA. Single molecule sequencing
revealed substantial binding of numerous miRNAs to nuclear
Ago2 (Figure 5D).
To further examine the potential for miRNA pathways to
operate in the nucleus, we tested the ability of Dicer, the enzyme
that processes pre-miRNA precursors, to generate mature
miRNAs in nuclear or cytoplasmic extracts. We performed an
in vitro processing assay in which we immunoprecipitated Dicer
from cytoplasmic or nuclear extracts, mixed it with radiolabeled
pre-miR-19a, and analyzed cleavage products by denaturing
polyacrylamide gel electrophoresis. We observed the expected
23 nucleotide product for both nuclear- and cytoplasmic-derived
Dicer (Figure 5E). These results suggest that Dicer can process
Figure 5. miRNAs Are in the Nucleus and Associate with Ago2
(A) Distribution of miRNAs by single molecule small RNA sequencing in nuclei versus whole cell.
(B and C) Relative abundance of top 20 miRNAs in whole-cell versus nuclear fractions.
(D) Top 20 miRNAs bound to nuclear Ago2 identified by immunoprecipitation and single molecule small RNA sequencing. Results are compared to a negative
control from immunoprecipitation using a nonspecific antibody (IgG).
(E) Detection of processing products from cytoplasmic and nuclear Dicer. RNAmolecular weight ladder is shown to the left (lane 1). Arrow indicates specific Dicer
processing product band.
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pre-miRNAs in the nucleus and is consistent with the potential
for nuclear regulation and production of small RNAs.
Small Duplex RNA Loading of Ago2 Is Deficient in
Nuclear Extract
Observed differences in fractionation of nuclear versus cyto-
plasmic RNAi factor complexes (Figure 3) suggested that other
differences between cytoplasmic and nuclear RISC might exist.
To extend our analysis, we tested whether there might be differ-
ences in small RNA loading between the nucleus and cytoplasm.
When examining Ago2 slicer activity in vitro (Figure 4D), our ex-
tracts were initially prepared from cells that were transfected with
siRNA. This protocol requires the RNA to pass through the cyto-
plasm before entering the nucleus, and therefore loading might
occur in the cytoplasm. Subsequent nuclear import of loaded
Ago2 complexes might then account for the slicer activity
observed in the nucleus (Ohrt et al., 2008; Weinmann et al.,
2009). To determine where loading was occurring, we added
small RNAs directly to nuclear extracts prepared from untreated
cells andsubsequently performed in vitroassays for slicer activity.
As we had observed previously, when Ago2 is isolated from
extracts of cells transfected with siLuc, Ago2 from both the
cytoplasm and nucleus can catalyze cleavage of the Luc
substrate RNA (Figure 6A, lanes 8 and 12). By contrast, extracts
fromuntransfectedcellswheredouble-strandedsiLucwasadded
after extractpreparation revealed that cytoplasmicAgo2wasable
tocatalyzecleavagebut thatnuclearAgo2was inactive (Figure6A,
lanes 6 and 10). These data are consistent with nuclear slicer
activity and replicateourprevious findings (Figure 4), but alsosug-
gest a deficiency in Ago2 loading in nuclear extracts.
We further examined the loading of single-stranded guide
RNA alone. Single-stranded RNAs are usually rapidly degraded
Figure 6. Duplex Small RNA Loading Is Deficient and RISC Loading Factors Are Absent in Nuclear Extracts
(A) Cleavage of a 50-radiolabeled luciferase RNA substrate by Ago2 isolated from cytoplasmic or nuclear fractions treated as shown above the gel. T1, RNase T1
cleavage; OH, alkaline hydrolysis; (+) CTRL, synthetic cleavage product.
(B) Coprecipitation of radiolabeled duplex siLuc or radiolabeled single-strand siLuc guide RNA incubated with Ago2 after immunoprecipitation from nuclear or
cytoplasmic extracts.
(C and D) In vitro assay for Ago2 duplex siRNA loading in extracts. Radiolabeled siRNA is added to extracts from human cell lines, Ago2 immunoprecipitated with
Ago2 or FLAG antibody, and copurified RNA resolved on a denaturing polyacrylamide gel. FHA-A2-c1 and FHA-A2-c3 are two different T47D clonal cell lines
stably expressing FLAG-HA-tagged Ago2.
(E) Radiolabeled siLuc was used in the same assay shown in (C) and (D), but copurified RNA was resolved on a nondenaturing polyacrylamide gel. Immuno-
precipitation wash conditions and shown below the gel and the copurified duplex or single-strand RNAs indicated to the right.
(F) Radiolabeled miR-19a or siLuc were used in the same assay shown in (C) and (D). Mismatch positions relative to the 50 end of the guide strand are indicated
above the gel.
(G) Western blot of RISC loading and maturation factors and subcellular markers from cytoplasmic and nuclear fractions.
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in cell extracts, precluding efficient loading. Nevertheless we
found that addition of the single-stranded siLuc guide strand
conferred low but similar levels of cleavage for both cytoplasmic
and nuclear Ago2 (Figure 6A, lanes 7 and 11).
RNA single strands can be directly bound by Ago2 without
the need for additional factors (Rivas et al., 2005). As a control
to ensure that nuclear Ago2 was accessible for loading, we
immunoprecipitated Ago2 and then incubated it with a radio-
labeled single-strand siLuc guide RNA. We found that both
cytoplasmic and nuclear Ago2 were able to bind the single-
stranded guide (Figures 6B and S5A). Taken together, our
observations that Ago2 from nuclear extract can (1) direct
cleavage of an RNA target after mixing with single-stranded
but not duplex RNA and (2) bind single-strand RNA are
consistent with the loading of duplex RNA being deficient in
cell nuclei.
Because duplex RNAs are susceptible to degradation by
nucleases (Braasch et al., 2003), we considered the possibility
that nuclear extracts could harbor a nuclease activity that might
interfere with loading. When duplex RNA was incubated with
either nuclear or cytoplasmic extracts, we observed similar
levels of degradation over time (Figure S5B), suggesting that
nuclease activity cannot explain our findings.
To more directly investigate Ago2 loading with duplex
small RNA, we developed an in vitro loading assay. We added
duplex siLuc with a radiolabeled guide strand to either nuclear
or cytoplasmic extracts. When Ago2 was immunoprecipitated
with antibodies against either endogenous or FLAG-tagged
Ago2, we observed copurification of radiolabeled siLuc guide
strand with cytoplasmic, but not nuclear, Ago2 (Figures 6C and
6D). A lack of nuclear loading was still observed when both siLuc
strands were radiolabeled, ruling out a potential passenger
strand loading bias in the nucleus (Figure S5C). We also
confirmed that similar amounts of Ago2 were immunoprecipi-
tated from both extracts in our experiments (Figure S5D).
Nuclear extracts are unlikely to support efficient ATP regenera-
tion for some RNAi processes (Klouwen and Appelman, 1967;
Zamore et al., 2000). Because RISC loading has been reported
to require ATP (Iwasaki et al., 2010), we used phosphocreatine
and creatine kinase (Calhoun and Swartz, 2007) to regenerate
ATP. We observed no change in loading in the nuclear extract
(Figure S5E), excluding insufficient ATP as a possible explana-
tion for the duplex loading deficiency.
Small duplex RNA loading involves an initial step when
the duplex first binds to RISC and an unwinding step when the
passenger strand is removed (Iwasaki et al., 2010; Matranga
et al., 2005; Ye et al., 2011). To determine the limiting step in
nuclear loading, we performed the in vitro Ago2 loading
assay under conditions that would discriminate between duplex
siRNA or single-strand guide RNA bound to Ago2. Immuno-
precipitations were washed with the standard high-salt (0.5 M
NaCl) buffer or with a low-salt (0.15 M NaCl) buffer to potentially
preserve formation of unstable Ago2-RNA complexes. When
RNA isolated from Ago2 immunoprecipitations was resolved
by native gel electrophoresis, both duplex and single-stranded
RNAs were bound to cytoplasmic Ago2, indicating formation
of both complexes during loading (Figure 6E). In contrast,
neither complex was formed during loading in nuclear extracts.
This result demonstrates that the initial step of duplex RNA
loading is deficient in nuclear extracts.
Our observation of miRNAs and Dicer activity in cell nuclei
(Figure 5) led us to examine loading of miRNAs. We tested
loading of a miR-19a duplex miRNA and duplex RNAs based
on siLuc that contained central or terminal mismatches. Like fully
complementary RNAs, we observed that mismatched duplexes
were loaded in cytoplasmic extract but were not loaded in
nuclear extract (Figure 6F). These results suggest that duplex
miRNAs may also be differentially loaded between the nucleus
and the cytoplasm.
Because several proteins are implicated in Ago2 loading and
RISC maturation (Iwasaki et al., 2010; Pare et al., 2013; Ye
et al., 2011), we performed western blot to detect their presence
in isolated nuclei. Surprisingly, these loading factors, Hsp90,
Translin, TRAX, Aha1, FKBP4, Cdc37 and p23, were all exclu-
sively cytoplasmic (Figure 6G). The only exception was Hsc70,
which was found in both the nucleus and the cytoplasm. These
results are consistent with a loading restriction to the cytoplasm
and suggest that programming of RNAi via Ago loading is regu-
lated by exclusion of critical loading factors from the nucleus.
DISCUSSION
There has been conflicting evidence over the presence and
activity of canonical RNAi factors in mammalian somatic cell
nuclei. The biological significance of the nucleus in the regulation
of RNAi pathways has also been unclear. This uncertainty has
obscured the potential for small RNAs to participate in the regu-
lation of nuclear processes. In this study, we used multiple
methods to test whether RNAi factors and RNAi activity could
be detected in mammalian cell nuclei. We employed protocols
for purifying nuclei that are free of ER protein contamination for
in vitro analyses and methods for visualizing RNAi factors and
RNAi activity in cell nuclei.
Our complementary experimental approaches support the
existence of nuclear RNAi but also indicate that it differs from
cytoplasmic RNAi. We find that (1) Ago2, the catalytic engine
of RNAi, and the RNAi factors Dicer, TRBP, and TNRC6A are
all present in human cell nuclei; (2) these nuclear-localized
RNAi factors can associate in stable multiprotein complexes;
(3) small RNAs can reduce levels of nuclear-localized RNA tar-
gets through site-specific cleavage; (4) Ago2 and Dicer isolated
from nuclei exhibit catalytic activity; (5) the effects of RNAi activ-
ity can be visualized inside of human cell nuclei by FISH; (6)
endogenous miRNAs are bound to nuclear Ago2 and miRNA
pathway components are in the nucleus; (7) programming of
RNAi through Ago2 loading with duplex small RNAs is not
observed in nuclear extracts; and (8) necessary RISC loading
and maturation factors are absent from the nucleus.
A previous study from Meister and colleagues reported on
the presence and complex formation of EGFP-tagged Ago2 in
human cell nuclei using fluorescence correlation and cross-
correlation spectroscopy (Ohrt et al., 2008). Consistent with their
results, we also observed Ago2 in the nucleus. However, they
found that nuclear EGFP-Ago2 did not appear to associate
with large complexes. These differences may be accounted for
by our focus on endogenous Ago2 and by variations in
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fractionation techniques. Based on spectroscopy data, Ohrt
et al. (2008) also proposed that Ago2 is loaded in the cytoplasm
and imported into the nucleus. Our data support this hypothesis
with biochemical evidence and provide a potential explanation
by observing a nuclear absence of the known RISC loading fac-
tors. The exclusion of RNAi programming from the nucleus has
important implications for RNAi because small RNAs that are pri-
marily nuclear may be loaded inefficiently or not at all. This par-
titioning of RISC loading may have evolved to regulate the
involvement of nuclear small RNA in RNAi-mediated processes.
The activity and regulation of RNAi factors in mammalian cell
nuclei might have multiple impacts on gene regulation. Small
RNAs could potentially guide RNAi factors like Argonaute to
nuclear RNA species, such as noncoding RNAs at gene pro-
moters to affect transcription or intronic RNA to alter splicing.
Nuclear RNAi-like pathways exist in various eukaryotic organ-
isms like plants, flies, worms, fungi, and ciliated protozoa (Castel
and Martienssen, 2013; Gagnon and Corey, 2012). These path-
ways have been characterized to regulate processes like nuclear
gene expression, epigenetic states, and genome maintenance
(Malone and Hannon, 2009). The demonstrated presence and
activity of canonical RNAi factors in mammalian cell nuclei sug-
gest that similar pathways may exist in humans.
We have recently reported a role for Ago2 and TNRC6A in
endogenous control of the inflammatory pathway genes cyclo-
oxygenase 2 (COX-2) and phospholipase 2G 4A (PLA2G4A)
by miR-589 miRNA (Matsui et al., 2013). COX-2 and PLA2G4A
are adjacent geneswhose promoters are linked by chromosomal
looping. miR-589 is expressed in A549 lung cancer cells and has
two seed sequence target sites at the COX-2 promoter. Elevated
levels of miR-589 lead to increased expression of both COX-2
and PLA2G4A. Ago2 and TNRC6A are recruited by miR-589 to
a sense transcript that overlaps the COX-2 promoter. When
Ago2 or TNRC6A levels are depleted, the activation of COX-2
and PLA2G4A by miR-589 is reversed. These results provide
an experimental demonstration that nuclear RNAi factors can
play a role in regulating a physiologically important regulatory
pathway.
Mammalian RNAi has typically been assumed to localize to the
cytoplasm, limiting the vision of researchers investigating the
regulation of gene expression. Clarity about RNAi factors and
their activity in the nucleus widens investigation of RNAi beyond
traditional targets in the cytoplasm to targets in the nucleus that
may regulate processes like transcription or splicing. Although
much remains to be learned about nuclear RNAi, such control
in the nucleus would add a new layer of gene regulation and offer
new options for RNAi-based therapeutics.
EXPERIMENTAL PROCEDURES
Tissue Culture and siRNA Transfection
HeLa, T47D, fibroblast, and A549 cells were cultured in their standardmedia at
37C in 5% CO2. Lipofectamine RNAiMAX (Invitrogen) was used to deliver
siRNAs into cells following the manufacturer’s recommended protocol.
Sequences of siRNAs used are listed in Table S1.
Nuclear and Cytoplasmic Cell Fractions
Cells were lysed in hypotonic lysis buffer (HLB) (10 mM Tris-HCl [pH 7.5],
10 mM NaCl, 3 mM MgCl2, 0.3% NP-40) supplemented with 1% Protease In-
hibitor (PI), 1 mM NaF, and 1 mM Na3VO4. Cells were spun and supernatant
kept as cytoplasmic extract after addition of NaCl to 0.15 M and glycerol to
10%. Pelleted nuclei were washed three times with HLB. To make nuclear
extract, nuclei were resuspended in nuclear lysis buffer (same as HLB but con-
taining 0.15 M NaCl and 10% glycerol) also supplemented with PI, NaF, and
Na3VO4. Nuclei were sonicated and supernatant kept as nuclear extract.
Coimmunoprecipitation
Protein G Plus/Protein A resin (Calbiochem), antibody and precleared nuclear
extract were mixed at 4C for 2–3 hr. When indicated, 20 mg RNase A was
added before incubation. Resin was washed with IP wash buffer (20 mM
Tris-HCl [pH 7.5], 0.4 M NaCl, 2 mM MgCl2, 0.05% NP-40, 0.025% SDS)
and copurified proteins eluted with SDS-PAGE loading buffer. Specific pro-
teins were detected by western blot.
Chromatographic Separation and Ammonium Sulfate Cuts of Cell
Extracts
For size-exclusion chromatography, extracts were either treated with RNase A
or SUPERase-In (Ambion), filtered, injected onto a Superdex 200HiLoad 16/60
column (Amersham Pharmacia) preequilibrated with FPLC buffer (20 mM Tris-
HCl [pH 7.5], 150 mM NaCl, 3 mM MgCl2, 5% glycerol), and separated by
FPLC. Eluted fractions were assayed by western blot. For subsequent frac-
tionation by anion exchange, size-exclusion fractions were concentrated
and injected onto a Mono-Q FPLC column (Amersham Pharmacia) equili-
brated with FPLC buffer at 0.1 M NaCl. Elution was performed by linear
gradient from 0.1 to 1 M NaCl. For ammonium sulfate precipitation, saturated
ammonium sulfate solution was added to cell extracts at the indicated final
percentages, incubated on ice for 15 min, spun down at 18,000 3 g at room
temperature, and pelleted precipitate resuspended in SDS loading buffer. Su-
pernatant was kept and additional ammonium sulfate added for the next cut.
Fractions were analyzed by western blot.
Analysis of siRNA-Mediated RNA Knockdown in Cellular
Compartments
HeLa cells were transfected with 25 nM siRNA and then harvested 72 hr later.
Cells were counted and fractionated similarly to above. However, instead of
sonicating, nuclei were lysed with modified Wuarin-Schibler buffer (MWS)
(10 mM Tris-HCl [pH 7.0], 4 mM EDTA, 0.3 M NaCl, 1 M urea, 1% NP-40)
(Wuarin and Schibler, 1994). Supernatant was kept as nucleoplasmic fraction
and chromatin washed. RNA was isolated from cytoplasmic and nucleo-
plasmic fractions by precipitation and Trizol extraction. RNA was isolated
from chromatin by Trizol extraction.
In Vitro Ago2 Cleavage Assay
HeLa cells were either untreated or transfected with 25 nM siLuc or siLuc_mm
(see Table S1) and then harvested 36 hr later, and nuclear and cytoplasmic
extracts were prepared. When indicated, siRNA or single-strand guide RNA
was incubated with extract from untreated cells for 1 hr at room temperature
with rotation. Ago2 was immunoprecipitated using Ago2 antibody (Abcam,
ab57113), Protein G Plus/Protein A agarose (Calbiochem), and 200 ml extract
at room temperature rotation for 1 hr. Resin was washed with IP wash buffer
(IPWB) (20 mM Tris-HCl [pH 7.5], 4 mM MgCl2, 0.5 M NaCl, 0.05% NP-40)
and then mixed with 50 radiolabeled synthetic target RNA substrate in 1 3
RNAi buffer (20 mM Tris-HCl [pH 7.5], 4 mM MgCl2, 0.5 mM DTT, 80 mM
NaCl, 20 mM KCl, 0.5 mM EDTA) supplemented with 1 mg/ml yeast tRNA,
20 units SUPERase-In (Ambion), and 0.5 mM ATP. Reactions were incubated
at 30C for 1.5 hr with periodic mixing, and then target RNA and cleavage
products were phenol extracted. Extracted RNAwas resolved on a 15%dena-
turing polyacrylamide sequencing gel. The gel was dried and exposed to a
phosphorimager screen overnight to visualize radioactive bands.
Immunofluorescence and Colocalization Analysis
Immunofluorescence was performed similarly to that previously described
(Ohrt et al., 2012; Spector, 2011) with modifications. Briefly, cells were grown
on 35 mm dishes with a 14 mm glass bottom. Cells were fixed in 2% formal-
dehyde or 4% paraformaldehyde. Fixed cells were then permeabilized with
0.2% Triton X-100 or 70% ethanol. Cells were incubated in primary antibody
Cell Reports 6, 211–221, January 16, 2014 ª2014 The Authors 219
in PBS + 1% normal goat serum (NGS), washed, incubated with secondary
antibody + 1% NGS, washed again, and then set in mounting medium with
DAPI and imaged. Cells were imaged by wide-field epifluorescence micro-
scopy and images processed by blind deconvolution with AutoQuant X3
(Media Cybernetics). Alternatively, some samples were imaged by Andor
spin disc confocal microscopy. Colocalization channels were calculated using
Imaris (Bitplane) based on the correlation of the strength of linear relation
between the two channels. Threshold levels for calculation were selected
above background.
Fluorescence in Situ Hybridization
Cells were grown on 35 mm MatTek dishes and transfected with 25 nM siLuc
or siMalat1 as described above. Cells were fixed in ice-cold 4% PFA and per-
meabilized in 70%. From this point forward, the protocol recommended by the
manufacturer of the FISH probes for Malat-1 (Biosearch Technologies, New
Stellaris RNA FISH Probe for Malat-1, SMF-2035-1) was followed. Cells
were set with mounting medium with DAPI and imaged as above for IF.
Small RNA Sequencing
Small RNA sequencing libraries were constructed from either whole-cell RNAs
or nuclear RNAs isolated from T47D cells and sequenced on Illumina Hiseq
2000. The reads were aligned to human genome hg19, UCSC miRNA data-
base, and/or miRBase (mature miRNA).
Ago2-associated miRNA in cell nucleus was isolated by RNA immunopre-
cipitation using a specific Ago2 antibody. Small RNA (<40 nt) including miRNA
was further isolated by gel purification. The small RNA was then subjected to
poly(A) tailing and sequenced on a single-molecule Helicos sequencer with a
Direct RNA Sequencing (DRS) module.
In Vitro Ago2 Small RNA Loading Assay
Duplex siRNA or single-strand guide RNA radiolabeled at the 50 end was incu-
bated with extract supplemented with 1 mM ATP for 1 hr at room temperature
with rotation. Ago2 was immunoprecipitated using Ago2 antibody (Abcam,
ab57113) and Protein G Plus/Protein A agarose (Calbiochem). Resin was
washed with IP wash buffer (IPWB) (20 mM Tris-HCl [pH 7.5], 4 mM MgCl2,
0.5 M NaCl, 0.05% NP-40) and then phenol-chloroform extract to isolate
copurified RNA. Extracted RNA was resolved on a 15% denaturing polyacryl-
amide sequencing gel or a 15% native TBE-buffered polyacrylamide gel. The
gel was dried and exposed to a phosphorimager screen overnight to visualize
radioactive bands.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, one table, and one movie and can be found with this article online
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Tissue culture and siRNA transfection 
HeLa cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 
5% fetal bovine serum (FBS) and 0.5% non-essential amino acids (NEAA). T47D cells 
(ATCC) were cultured in RPMI medium supplemented with 10% FBS, 0.5% NEAA, 20 µg/mL 
insulin, 10 mM pH 7.0-7.6 HEPES, and 1 mM sodium pyruvate.  Fibroblast cells (Coriell 
Institute, GM04281) were cultured in minimum essential medium (MEM) supplemented with 
10% FBS and 0.5% NEAA. A549 cells (ATCC) were cultured in F-12K medium supplemented 
with 10% FBS. T47D cells stably expressing FLAG-HA-tagged Ago2 were cultured identically 
to T47D cells but media supplemented with 0.2 mg/mL G418. All cells were grown at 37°C in 
5% CO2.   
Lipofectamine RNAiMAX (Invitrogen) was used to deliver siRNAs into HeLa cells 
following the manufacturer's recommended protocol in OptiMEM low serum medium 
(Invitrogen). Growth media was changed to full medium after 24 h. Transfected cells were 
harvested 72 h after transfection for qPCR and RACE analyses, 36 h after transfection for in 
vitro Ago2 cleavage assays, and 48 h after transfection for FISH analysis. Sequences of 
siRNAs used are listed in Table S1. 
 
Nuclear and cytoplasmic cell fractions 
Cells were harvested with trypsin-EDTA solution (Invitrogen), washed with PBS then 
resuspended in ice-cold hypotonic lysis buffer (HLB) (10 mM Tris-HCl, pH 7.5, 10 mM NaCl, 
3 mM MgCl2, 0.3% NP-40) supplemented with 1% Protease Inhibitor Cocktail Set I 
(Calbiochem), 1 mM sodium fluoride and 1 mM sodium orthovanadate at a final of 1 mL/75 
mg wet cell pellet. After incubation on ice for 15 min and gentle pipetting, lysate was spun at 
4°C at 800xg for 5 min. The supernatant was kept as cytoplasmic extract and NaCl and 
glycerol were added to a final of 140 mM and 10%, respectively. Pelleted nuclei were washed 
3x with ice-cold HLB by 5 min incubation on ice, pipetting and vortexing, then spinning at 4°C 
at 100-200xg for 2 min. For nuclear extracts, nuclei were resuspended in ice-cold nuclear 
lysis buffer (NLB) (20 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 3 mM MgCl2, 0.3% NP-40, 10% 
glycerol) supplemented with 1% Protease Inhibitor Cocktail Set I, 1 mM sodium fluoride and 1 
mM sodium orthovanadate at a final of 0.5 mL/75 mg of original wet cell pellet weight (1/2 the 
volume of cytoplasmic fraction). Nuclei were sonicated on ice at 20% power 3x for 15 sec in 4 
mL volumes. After high speed centrifugation at 4°C for 15 min to remove insoluble cell debris, 
the soluble fraction was kept as nuclear extract.  All extracts were aliquoted, flash-frozen in 
liquid nitrogen, then stored at -80°C for later use.  Prior to use, extracts were spun again or 
filtered through 0.45 µm filter units.  
 
Optimization of nuclei isolation protocol 
A protocol similar to the above described for nuclear and cytoplasmic fraction preparation 
was followed except detergent was either omitted or TWEEN-20, NP-40 or Triton X-100 non-
ionic detergents were included in HLB at the indicated concentrations. After the final nuclei 
wash, a fraction of the nuclei were aliquoted for visualization by fluorescence microscopy 
while the remaining nuclei were resuspended in NLB and sonicated to prepare nuclear 
extracts as described above. Nuclei were prepared for microscopy by washing 1x in ice-cold 
PBS then incubating in PBS + 1 µM ER Tracker Red (Invitrogen) for 20 min on ice. Nuclei 
were washed in ice-cold PBS then diluted 10-fold in ice-cold PBS + 4% paraformaldahyde 
and incubated on ice 10 min. Nuclei were resuspended by pipetting and spotted on  glass 
slides. After partial air-drying, one drop of Vectashield Hard Set Mounting Medium with DAPI 
(Vector Laboratories, H-1500) was added, a coverslip added and mounting media allowed to 
harden at room temperature for 15 min.  
Nuclei were visualized with a 60x objective lens and DAPI and TRITC filters on a wide-
field epifluorescence Deltavision microscope. Z-sections were taken at 0.15 µm thickness. 
Images were deconvoluted by blind deconvolution using AutoQuant X3 (Media Cybernetics), 
stacked and ER tracker staining pseudo-colored yellow in ImageJ for visualization.     
 
Western blot analysis 
Cell extracts were prepared as described above. For comparing nuclear and cytoplasmic 
fractions by Western blot, the same cell equivalents of extract were separated by 
electrophoresis (1/2 the volume of nuclear extract for every 1 volume of cytoplasmic). In 
general, loading equal amounts of total protein is unsatisfactory for comparing the nuclear 
and cytoplasmic levels of specific proteins since there is approximately 4-fold more total 
protein in cytoplasmic extracts. Protein was separated on 4-20% gradient SDS-PAGE TGX 
pre-cast gels (Biorad) at 100 V for 75 min. After gel electrophoresis, proteins were transferred 
to nitrocellulose membrane (Hybond-C Extra, GE Healthcare Life Sciences) at 100 V for 90 
min. Membranes were blocked for 30 min at room temperature with 5% milk protein in PBS + 
0.05% TWEEN-20 (PBST).  
Blocked membranes were incubated with the following specific primary antibodies for 
16 h at 4°C in PBST + 5% milk with rocking: anti-Ago2 at 1:1000 (Abcam, ab57113), anti-
TNRC6A at 1:4000 (Bethyl Laboratories, A302-329A) or anti-TNRC6A at 1:3000 (kind gift 
from Edward Chan, Univ. Florida, rb5182), anti-Dicer at 1:1000 (Abcam, ab14601), anti-
TRBP at 1:1000 (Abcam, ab72110) or anti-TRBP at 1:3000 (kind gift from Qinghua Liu lab); 
anti-Calreticulin at 1:1500 (Cell Signaling, 2891S), anti-Calnexin at 1:1500 (Cell Signaling, 
2433S), anti-Histone H3 at 1:10000 (Abcam, ab1791), anti-Lamin A/C at 1:1500 (Abcam, 
ab8984), anti-OxPhos at 1:1000 (Invitrogen, A21351), anti-tubulin at 1:6000 (Sigma-Aldrich, 
T5201), anti-Ago1 at 1:1000 (Wako Chemical, 015-22411), anti-Ago3 at 1:500 (Active Motif, 
39788); anti-Ago4 at 1:500 (Active Motif, 39856), anti-PACT at 1:1000 (Abcam, ab75749), 
anti-Hsp90 at 1:500 (Enzo Life Sci., ADI-SPA-830-D), anti-Hsc70 at 1:500 (Enzo Life Sci., 
ADI-SPA-810-D), anti-Aha1 at 1:1000 (Abcam, ab56721), anti-FKBP4 at 1:50000 (Abcam, 
ab124906), anti-Cdc37 at 1:50000 (Abcam, ab108305), anti-p23 at 1:1000 (Abcam, ab2814).  
After primary antibody incubation, membranes were washed 3x for 5 min at room 
temperature with PBST then incubated for 30-45 min at room temperature with HRP-
conjugated anti-mouse at 1:10000 (Jackson Laboratories, 715-035-150) or anti-rabbit at 
1:5000 (Jackson Laboratories, 711-035-152) in PBST + 5% milk. Membranes were washed 
again 3x for 15 min in PBST at room temperature, then protein bands visualized using 
SuperSignal West Pico Chemiluminescent  Substrate (Thermo Scientific). For quantification 
of RNAi factor protein levels from Western blots of cellular fractions, films were scanned and 
bands quantified using ImageJ.   
 
Co-immunoprecipitation 
Co-immunoprecipitation experiments were performed by mixing 40 µl of Protein G 
Plus/Protein A resin (Calbiochem), 2 µg of antibody and nuclear extract (~0.5-1 mg total 
protein, precleared at 4°C for 30 min using ~15 µL Protein G Plus/Protein A resin and ~0.3 µg 
of corresponding IgG) and rotating at 4°C for 2-3 h.  Resin was washed 4x with IP wash 
buffer (20 mM Tris-HCl, pH 7.5, 0.4 M NaCl, 2 mM MgCl2, 0.05% NP-40, 0.025% SDS) and 
co-purified proteins eluted by boiling resin in 25 µl 1x SDS loading buffer.  Eluted protein was 
resolved by SDS-PAGE and proteins detected by Western blot as described above. When 
indicated, 20 µg of RNase A was added before incubation. For FLAG-tagged Ago2 co-
immunoprecipitation, about 20 µL ANTI-FLAG-M2 affinity gel (Sigma) and nuclear extract 
from T47D cells stably expressing FLAG-HA-tagged Ago2 (~0.5-1 mg total protein) were 
rotated at 4°C for ~1.5-2.5 h, followed by washing and elution as described above.  
 
Chromatographic and ammonium sulfate fractionation of cell extracts 
Nuclear extracts were prepared as described above but concentrated 2-fold by using 1/2 the 
standard amount of NLB during nuclei resuspension and sonication. For size-exclusion 
chromatography, 2 mL of nuclear extract was either treated with 50 µg of RNase A or 200 
units of SUPERase-In (Ambion) for 1 h at room temperature. Samples were then spun down 
at high speed and 0.45 µm filtered and injected onto a Superdex 200 HiLoad 16/60 FPLC 
column (Amersham Pharmacia) that was pre-equilibrated with FPLC buffer (20 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 3 mM MgCl2, 5% glycerol). Protein was eluted off the column with 
FPLC buffer and the elution collected in fractions at 4°C that were then snap-frozen in liquid 
nitrogen and stored at -80°C. Western blot analysis of fractions was performed as described 
above. For subsequent tandem fractionation by anion exchange, size-exclusion fractions 
were concentrated 3-fold and diluted to 0.1 M NaCl and injected onto a Mono-Q FPLC 
column (Amersham Pharmacia) equilibrated with FPLC buffer at 0.1 M NaCl. Elution was 
performed at room temperature with a linear gradient from 0.1 to 1 M NaCl in FPLC buffer. 
Fractions were collected and snap-frozen in liquid nitrogen.  Western blot analysis was 
performed as described above.   
 Ammonium sulfate cuts were performed by addition of saturated ammonium sulfate 
solution to the extract up to the indicated final percentage and incubated on ice for 15 min. 
Precipitated protein was pelleted by centrifugation at 18,000xg for 20 min at 4°C. Supernatant 
was kept and additional ammonium sulfate added up to the next indicated percentage and 
incubation and centrifugation repeated. Precipitated protein pellets were resuspended in 
identical volumes of SDS loading buffer, resolved by SDS-PAGE and probed by Western blot 
as described above.  
 
Analysis of siRNA-mediated RNA knock-down in cellular compartments  
HeLa cells were transfected in quadruplicate with 25 nM siRNA then harvested 72 h later with 
trypsin-EDTA solution. Cells were washed with PBS then counted with a hemocytometer.  
Five million cells were aliquoted and resuspended in 380 µL of ice-cold hypotonic lysis bufer 
(HLB) (10 mM Tris, pH 7.5, 10 mM NaCl, 3 mM MgCl2, 0.3% NP-40) and incubated on ice for 
15 min.  Lysate was pipetted and spun at 500xg at 4°C for 5 min. Supernatant was kept as 
cytoplasmic fraction, 40 µL of 3 M sodium acetate, pH 5.5, added, 100% ethanol added up to 
70%, and precipitated at -20°C overnight.  
Pelleted nuclei were washed 3x with ice-cold HLB and pipetting and vortexing then 
resuspended in 380 µL of ice-cold modified Wuarin-Schibler buffer (MWS) (10 mM Tris-HCl, 
pH 7.0, 4 mM EDTA, 0.3 M NaCl, 1 M urea, 1% NP-40) (Wuarin and Schibler, 1994). Sample 
was incubated on ice for 30 min. with vortexing every 10 min., then spun at 500xg at 4°C for 
5 min. Supernatant was kept as nucleoplasmic fraction, 40 µL of 3 M sodium acetate, pH 5.5, 
added, 100% ethanol added up to 70%, and precipitated at -20°C overnight.  
Pelleted chromatin was washed 3x with ice-cold MWS then 1 mL Trizol (Invitrogen) 
was added to the final chromatin pellet. To process cytoplasmic and nucleoplasmic fractions, 
precipitates were pelleted at 18000xg for 15 min at 4°C then 1 mL Trizol added to each pellet. 
Samples in Trizol were heated to 70°C with vortexing until completely dissolved (5-10 min), 
then cooled to room temperature. To each sample 0.2 mL chloroform:isoamyl alcohol (24:1) 
was added, samples vortexed, then spun at 18000xg for 10 min.  The top aqueous layer was 
collected and RNA precipitated by addition of 1 volume of isopropanol and incubation at -
20°C overnight. RNA was pelleted by spinning at 18000xg, washed with 70% ethanol, then 
air dried and prepared for quantitative PCR or 5' RACE.          
 
Quantitative PCR 
Identical volumes of RNA (representing approximately the same number of cells and ranging 
from 1-2 µg of RNA) that were prepared from cellular fractions above were treated with 2 
units of DNase I (Worthington) in 9.5 µL of DNase I buffer (10 mM Tris-HCl, pH 7.0, 10 mM 
NaCl, 2 mM MgCl2, 0.5 mM CaCl2) for 15 min at room temperature to degrade any genomic 
DNA contamination. Afterwards, 0.5 µL of a 50 mM EDTA, 10 mM EGTA solution was added 
and DNase I heat-inactivated at 70°C for 10 min. Treated RNAs were reverse-transcribed 
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) in a final 
volume of 20 µL. Quantitative PCR (qPCR) was performed using iTaq Supermix with ROX 
(Biorad) with ~10-20 ng of cDNA as template.  
 Data were normalized relative to measured GAPDH levels in each cellular 
compartment. Because no normalization control exists that is the same level across cellular 
compartments, and because spike-in controls can have variability in performance (data not 
shown), comparisons among treatments were only performed within each cellular 
compartment and not across cellular compartments (ie. chromatin to chromatin, not 
cytoplasm to chromatin).  Primers used in qPCR are listed in Table S1. 
 
Rapid Amplification of cDNA Ends (RACE)  
RACE was performed using the GeneRacer Kit (Invitrogen) following the manufacturer's 
recommended protocol. cDNA was prepared from ~1 µg RNA from each cellular fraction 
(DNase-treated and prepared as described above) by reverse-transcription (RT) reaction 
using random primers. The 5’ end of cDNA was amplified using Platinum Taq DNA 
polymerase (Invitrogen) and specific primer sets for Malat1 and RPL30 (Table S1). The 
thermal cycling condition was 94°C for 2 min, followed by 5 cycles of 94°C for 30 sec and 
72°C for 1 min, 5 cycles of 94°C for 30 sec and 70°C for 1 min, and 25 cycles of 94°C for 30 
sec, 65-66°C for 30 sec, and 68°C for 1 min, followed by final extension of 68°C for 10 min. 
PCR products were analyzed on 1.2-1.5% agarose gel (Fig. S6B-C). Major PCR products on 
gels were excised and cloned into pCR 4-TOPO vectors, transformed into TOP10 chemically 
competent cells, then sequenced to map the 5’ cleavage sites. Chromatin-associated 
cleavage products for RPL30 were below our detection limit (Fig. S6C), despite performing 
nested PCR with multiple primer sets (data not shown). This result may reflect the relatively 
low level of RPL30 mRNA actually associated with chromatin. In addition to relative starting 
levels of targeted RNA, detection of cleavage products will also depend upon other factors 
like the rate of cleavage product formation and degradation. 
 
In vitro Ago2 cleavage assay 
HeLa cells were either untreated or transfected with 25 nM siLuc or siLuc_mm (see Table S1) 
then harvested 36 h later and nuclear and cytoplasmic extracts prepared as described above. 
Ago2 protein was immunoprecipitated using 1.5 µg anti-Ago2 antibody (Abcam, ab57113), 30 
µL Protein G Plus/Protein A agarose (Calbiochem) and 200 µL extract with rocking at room 
temperature for 1 h. Resin was washed 3x with 0.5 mL IPWB500 (20 mM Tris-HCl, pH 7.5, 4 
mM MgCl2, 0.5 M NaCl, 0.05% NP-40) then 1x with 0.5 mL IPDB (20 mM Tris-HCl, pH 7.5, 3 
mM MgCl2, 0.15 M NaCl) at room temperature. Synthesized target RNA substrate was 5' 
radiolabeled with T4 polynucleotide kinase and [γ]32P-ATP, then gel-purified. Labeled target 
RNA substrate (50,000 cpms, ~0.1 pmols) was added to the washed Ago2-bound resin in 20 
µL 1X RNAi buffer (20 mM Tris-HCl, pH 7.5, 4 mM MgCl2, 0.5 mM DTT, 80 mM NaCl, 20 mM 
KCl, 0.5 mM EDTA) supplemented with 1 mg/mL yeast tRNA, 20 units SUPERase-In 
(Ambion), and 0.5 mM ATP.  
Reactions were incubated at 30°C for 1.5 hr with periodic mixing and RNA collected by 
addition of 0.5 µL of 0.5 M EDTA then phenol extracted. Extracted RNA was precipitated with 
9 volumes of 2% LiClO4 in acetone, washed with acetone, resuspended in 90% formamide, 
1x Tris-Borate EDTA (TBE) buffer, boiled for 3 min, then resolved on a 15% denaturing 
polyacrylamide (7 M urea, 1x TBE, 2% glycerol) sequencing gel. The gel was dried and 
exposed to a phosphorimager screen overnight to visualize radioactive bands. Target RNA 
substrate consists of a single siLuc siRNA target site flanked by firefly luciferase gene 
sequence and capped with two terminal DNA bases on each end. Target RNA substrate 
sequence (DNA bases capitalized, complementary siRNA target site in brackets): 
GAacaauugauuuuacagac[gcacauaucgaggugaaca]ucacguacgcggaauacuTC.  
Synthetic product RNA sequence: GAacaauugauuuuacagac[gcacauauc.     
 
Immuno-fluorescence and co-localization analysis 
Immuno-fluorescence was performed similarly to that previously described (Ohrt et al., 2012; 
Spector, 2011) with modifications. Briefly, cells were grown for 16-24 h to 50-70% confluency 
on 35 mm dishes (MatTek Corporation, P35GCOL-1.5-14-C) with a 14 mm glass bottom of 
1.5 mm thickness. Cells were washed with PBS then fixed in freshly made 2% formaldehyde 
in PBS or 4% paraformaldehyde in PBS for 15 min at 20°C, or in 70% ethanol for at least 30 
min at 4°C. Fixed cells were washed 3x in PBS for 10 min at 4°C. Cells were permeabilized in 
PBS containing 0.2% Triton X-100 and 1% normal goat serum (NGS) for 5-10 min on ice then 
washed 3x with ice-cold PBS + 1% NGS at 4°C for 10 min.  
The cells were incubated in primary antibody for 1 hr at room temperature or 
overnight at 4°C. Primary antibodies were diluted in PBS + 1% NGS and incubated for 1 h at 
room temperature or at 4°C overnight: anti-Ago2 at 1:100 (Abcam, ab57113), anti-Ago2 at 
1:50 or 1:100 (Sigma-Aldrich, clone 11A9, SAB4200085), anti-Ago2 at 1:50 or 1:100 (Wako 
Chemicals, 015-22031), anti-TNRC6A at 1:50 or 1:100 (Bethyl Laboratories, A302-329A), 
anti-Dicer at 1:100 (Abcam, ab14601), anti-TRBP at 1:100 (Abcam, ab72110). Cells were 
washed 3x in PBS + 1% NGS for 10 min at room temperature, then incubated in 4 µg/mL 
secondary antibody diluted in PBS + 1% NGS for 1 h at room temperature. Secondary 
antibodies were Alexa Fluor 488 Goat Anti-Mouse IgG (Invitrogen, A-11001), Alexa Fluor 594 
Goat Anti-Rabbit IgG (Invitrogen, A-11012), and Alexa 594 Goat Anti-Rat IgG (Invitrogen, A-
11007). Cells were washed 4x in PBS for 10 min at room temperature then Vectashield Hard 
Set Mounting Medium with DAPI (Vector Laboratories, H-1500) was added to the cells then 
covered with a coverslip and allowed to harden for 15 min at room temperature.  
Cells were imaged with a 60x objective lens and DAPI, FITC and TRITC filters on a 
wide-field epifluorescence Deltavision deconvolution microscope. Z-sections were taken at 
0.1, 0.15 or 0.2 µm for at least 6 µm thickness. Images were blind deconvoluted using 
AutoQuant X3 (Media Cybernetics) and stacked and analyzed in Imaris (Bitplane). 
Alternatively, some samples were imaged by Andor spin disc confocal microscopy. The Co-
localization channel of Ago2 (FITC, green) and TNRC6A (TRITC, red) was calculated using 
Imaris software based on the correlation of the strength of linear relation between the red 
channel and the green channel and the threshold levels for calculation of co-localization were 
selected above background signals.  
 
Fluorescence in situ hybridization (FISH) 
Cells were grown for 16-24hrs to 50-70% confluence on 35mm MatTek dishes as described 
for immuno-fluorescence above. Cells were transfected with 25 nM siLuc or siMalat1 as 
described above. At 48 h post transfection, cells were washed with PBS and fixed in ice-cold 
4% paraformaldehyde in PBS for 15 min at 20°C, followed by permeabilization in 70% 
ethanol for at least 30 min at 4°C.  
From this point forward, the protocol recommended by the manufacturer of the FISH 
probes for Malat-1 (Biosearch Technologies, New Stellaris RNA FISH Probe for Malat-1, 
SMF-2035-1) was followed with modifications. Briefly, cells were washed with 1 mL of wash 
buffer (10% formamide in 2x SSC) and incubated 5 min at room temperature, then incubated 
in hybridization buffer (10% formamide, 2x SSC, 100 mg/mL dextran sulfate, 1 mM vanadyl 
ribonucleoside complex) containing Malat-1 probe (125 nM) in a humidified chamber at 37°C 
for 4-16 h in the dark. Cells were washed 1x with wash buffer in the dark at 37°C for 30 min. 
Vectashield Hard Set Mounting Medium with DAPI (Vector Laboratories, H-1500) was then 
added, covered with a coverslip and allowed to harden for 15 min at room temperature. Cells 
were imaged and analyzed the same as described above for immuno-fluorescence but using 
DAPI and Cy-5 filters. Z-stacks were taken with 0.15 or 0.2 µm slices and 6 µm thickness. 
 
Small RNA-seq library preparation and sequencing 
For whole cell small RNA sequencing, T47D cells were harvested and then dissolved in 
TRIzol (Sigma). For sequencing of small RNA from cell nuclei, pure nuclei were isolated first 
as described above. Nuclei were then dissolved in TRIzol. Small RNA was isolated using 
miRNeasy Mini Kit (Qiagen) and then treated with DNase I (Worthington) for 20 min at 37°C 
to remove any contaminating genomic DNA. The small RNA-seq library was made using 
Illumina Small RNA Truseq kit following the manufacturer's recommended protocol. RNA-seq 
libraries were sequenced on a Illumina HiSeq 2000 as per manufacturer’s instructions for 
single-end 1x50. Approximately, 30 million raw reads (averaged over two replicates) were 
obtained per sample. Reads with low quality score were removed and reads that passed the 
filtration were trimmed by removing the adaptor sequence. Trimmed reads shorter than 15 nt 
were also excluded from analysis. Filtered and trimmed reads were aligned to the human 
genome (hg19) using Bowtie2 by allowing up to two mismatches to the reference sequence. 
Up to 10 different alignments per read were permitted. For reads that were aligned to multiple 
positions in the reference genome, the single aligned read with the fewest mismatches was 
selected using a Perl script. If multiple reads still remained, the original read would be 
disregarded. Approximately 70% of raw reads were successfully aligned. Finally, the aligned 
reads were again mapped to the UCSC miRNA database and miRBase (mature miRNAs) to 
search for possible miRNA hits. 
 
Sequencing of AGO2-associated small RNA in cell nuclei  
RNA Immunoprecipitation (RIP) assay using nuclear lysate (T47D cells) was performed as 
described (Chu et al., 2010; Matsui et al., 2013) using anti-human Ago2 antibody (Wako 
Chemical, 015-22031). A non-specific mouse IgG antibody was used as a control. The 
isolated RNA was loaded on a 10% polyacrylamide gel and the small RNA fraction (15nt-
40nt) was cut out and extracted. The small RNA was then subjected to polyadenylation by 
using a poly(A) tailing kit (Ambion). 3′-deoxy-ATP (cordycepin triphosphate, Jena 
Biosciences) was introduced 10 min after the initiation of the polyadenylation reaction for 3′-
end blocking and tail length limitation (performed by Helicos, Inc.). The Direct RNA 
Sequencing (DRS) was carried out on a single molecule Helicos sequencer. Raw sequencing 
data was filtered to remove low quality reads and subsequently aligned using the Helisphere 
package, a software designed to specifically analyze sequencing data generated from the 
Helicos sequencer. The aligned reads were again mapped to the UCSC miRNA database 
and miRBase (mature miRNAs) to search for possible miRNA hits. 
 
In vitro Dicer processing assay 
Dicer was immunoprecipitated using 3 µg of anti-Dicer (Abcam, ab14601) antibody (or 3 µg 
normal mouse IgG as control), 50 µL Protein G Plus/Protein A agarose (Calbiochem) and 200 
µL of HeLa nuclear or cytoplasmic extract (prepared as described above) with rotation at 
room temperature for 1 h. Resin was washed 3x with 0.5 mL IPWB300 (20 mM Tris-HCl, pH 
7.5, 4 mM MgCl2, 0.3 M NaCl, 0.05% NP-40) then 1x with 0.5 mL IPDB (20 mM Tris-HCl, pH 
7.5, 3 mM MgCl2, 0.15 M NaCl) at room temperature. Pre-miR-19a substrate was in vitro 
transcribed in the presence of [α]32P-ATP then gel-purified. Radiolabeled pre-miR-19a RNA 
(50,000 cpms) was added to the washed Dicer-bound resin in 20 µL 1X Dicer assay buffer 
(40 mM Tris-HCl, pH 7, 3 mM MgCl2, 50 mM NaCl) supplemented with 2 mM ATP and 200 
units SUPERase-In (Ambion).  
Reactions were incubated at 32°C for 1 hr with periodic mixing and RNA collected by 
addition of 0.5 µL of 0.5 M EDTA and 5 µg yeast tRNA then phenol extracted. Extracted RNA 
was precipitated with 9 volumes of 2% LiClO4 in acetone, washed with acetone, resuspended 
in 90% formamide, 1x Tris-Borate EDTA (TBE) buffer, boiled for 3 min, then resolved on a 
15% denaturing polyacrylamide (7 M urea, 1x TBE, 2% glycerol) sequencing gel. The gel was 
dried and exposed to a phosphorimager screen overnight to visualize radioactive bands. Pre-
miR-19a sequence from miRBase was used prepare in vitro transcription template. DNA 
seqeunces below were annealed and used for in vitro transcription (Epicentre Ampliscribe T7 
In Vitro Transcription Kit) following the manufacturers protocol. 
hsa-miR-19a pre-miRNA T7 sense (lowercase = T7 promoter):  
ctaatacgactcactataGCAGTCCTCTGTTAGTTTTGCATAGTTGCACTACAAGAAGAATGTAGT
TGTGCAAATCTATGCAAAACTGATGGTGGCCTGC  
hsa-miR-19a pre-miRNA T7 antisense (lowercase = T7 promoter):  
GCAGGCCACCATCAGTTTTGCATAGATTTGCACAACTACATTCTTCTTGTAGTGCAACTA
TGCAAAACTAACAGAGGACTGCtatagtgagtcgtattag 
 
In vitro Ago2 small RNA loading assay 
Duplex siRNA or single-strand guide RNA radiolabeled at the 5' end was incubated with cell 
extracts supplemented with 1 mM ATP for 1 h at room temperature with rotation. For 
reactions using mismatch-containing siLuc, the standard antisense siLuc strand was 
radiolabeled and annealed to sense strand with the indicated base position mismatches (see 
Table S1) then gel-purified before use. When indicated, phosphocreatine (10 mM) and 
creatine kinase (100 µg/mL) were added as an ATP regeneration system. Ago2 was 
immunoprecipitated using 2µg of anti-Ago2 antibody (Abcam, ab57113) and 40 µL of Protein 
G Plus/Protein A agarose (Calbiochem) with rotation for 1 h at room temperature. Resin was 
washed 3x with 0.8 mL IPWB500 (20 mM Tris-HCl, pH 7.5, 4 mM MgCl2, 0.5 M NaCl, 0.05% 
NP-40) and 1x with 0.5 mL IPDB (20 mM Tris-HCl, pH 7.5, 3 mM MgCl2, 0.15 M NaCl) at 
room temperature. Co-precipitated RNA was collected by addition of 0.5 µL of 0.5 M EDTA 
and 5 µg yeast tRNA then phenol-chloroform extraction. Extracted RNA was precipitated with 
9 volumes of 2% LiClO4 in acetone, washed with acetone, resuspended in 90% formamide, 
1x Tris-Borate EDTA (TBE) buffer, boiled for 3 min, then resolved on a 15% denaturing 
polyacrylamide (7M urea, 1x TBE, 2% glycerol) sequencing gel. The gel was dried and 
exposed to a phosphorimager screen overnight to visualize radioactive bands.   
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Figure S2, Related to Figure 2: Argonaute family proteins are detected in HeLa nuclear extracts by Western 
blot. Cell extracts were prepared as described and probed by Western blot with specific antibodies to detect each Ago 
family protein, Ago1, Ago2, Ago3 and Ago4. 
Figure S3, Related to Figure 3: Ago2 and TNRC6A immuno-staining co-localizes in HeLa cell nuclei. Cells were 
stained with anti-Ago2 from Abcam (A) or anti-Ago2 from Wako Chemicals (B) and anti-TNRC6A from Bethyl
Laboratories (see Methods). (A) 4 µm thick and (B) 5 µm thick Z-stacks were taken.  Co-localization channels were built 
in Imaris (Bitplane). Scale bars = 10 µm (A) and 5 µm (B). 
Figure S4, Related to Figure 4: 5’-RACE and Malat-1 FISH demonstrate siRNA-directed cleavage in nuclear 
fractions. HeLa cells were transfected with siRNA against Malat-1 lncRNA, RPL30 mRNA, with a negative control 
siRNA (siLuc) or left untreated. RNA from cytoplasmic, nucleoplasmic and chromatin fractions were isolated 72 h 
post-transfection and subjected to 5’RACE to detect predicted cleavage products for (A) Malat-1 or (B) RPL30 
(see Methods). Gels for separation of RACE products are shown with the cleavage product band highlighted. 
Cleavage product bands were excised and sequenced to unambiguously validate sequence-specific siRNA-
directed cleavage at the expected phosphodiester bond of the targeted RNA. 5’ ends of sequenced RACE 
products are shown below each gel for each cell fraction. RACE was performed at least twice and cloning and 
sequencing performed several times per band for each experiment. HeLa cells were treated with (C) a mock 
siRNA (siLuc) or (D) siRNA against Malat-1 (siMalat1) then processed for FISH analysis (see Methods) 48 h later. 
Z-stacks 6 µm thick were taken.
Figure S5, Related to Figure 6: Controls for Ago2 loading deficiency in the human cell nucleus. (A) Incubation of 
single-stranded siLuc guide RNA with T47D cytoplasmic and nuclear extracts followed by Ago2 immunoprecipitation, or 
with Ago2 after immunoprecipitation. Single-stranded guide RNA does not efficiently bind Ago2 in extracts presumably 
due to rapid degradation. If Ago2 is first immunoprecipitated to wash away contaminating nucleases, single-stranded 
guide RNA readily binds and co-immunoprecipitates. (B) Degradation kinetics of duplex siLuc in HeLa cytoplasmic or 
nuclear extracts. (+) SUPERase-In = addition of 50 unites of SUPERase-In RNase inhibitor. (C) Ago2 in vitro loading 
assay using siLuc siRNA dual-labeled on both guide and passenger strands. (D) Immunoprecipitation of Ago2 from 
HeLa cytoplasmic and nuclear extracts followed by coomassie staining shows equivalent amounts of Ago2 capture from 
both extracts. (E) Ago2 in vitro loading assay using radiolabeled siLuc and the addition of ATP regeneration system 
(see Extended Methods) in cytoplasmic or nuclear extracts.

Movie S1, Related to Figure 1: 5 µm section from bottom to top of HeLa cells stained with anti-Ago2 (green) 
from Wako Chemicals.  Nuclei are stained with DAPI (blue).
